Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A

Biopharmaceutics and Drug Disposition

Volumn 19, Issue 2, 1998, Pages 79-89

  Choi, Yun J ^a   Lee, Hee J ^a   Kwon, Jong W ^b   Kim, Won B ^b   Yang, Junnick ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

3 methylcholanthrene; Chloramphenicol; DA 125; M1, M2, M3, M4; Pharmacokinetics; Phenobarbital; SKF 525A

Indexed keywords

3 METHYLCHOLANTHRENE; ANTINEOPLASTIC AGENT; CHLORAMPHENICOL; CYTOCHROME P450; DOXORUBICIN; DRUG METABOLITE; GALARUBICIN; PHENOBARBITAL; PROADIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RAT;

ANIMALS; ANTHRACYCLINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; CARCINOGENS; CAROTID ARTERIES; CHLORAMPHENICOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME INHIBITORS; INJECTIONS, INTRAVENOUS; JUGULAR VEINS; MALE; METHYLCHOLANTHRENE; PHENOBARBITAL; PROADIFEN; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031893685     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199803)19:2<79::AID-BDD79>3.0.CO;2-O     Document Type: Article

References (17)

1. H.J. Shim, E.D. Lee, E.J. Yoon, S.D. Lee, W.B. Kim, J. Yang and M.C. Lee, Simultaneous determination of a new anthracycline, DA-125, and its metabolites M1, M2, M3 and M4 in plasma and urine by high-performance liquid chromatography. J. Chromatogr., 656, 407-414 (1994).
2. H.J. Shim, E.D. Lee, E.J. Yoon, S.D. Lee, W.B. Kim, J. Yang and M.G. Lee, Pharmacokinetics of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM, or FT-ADM to rats. A new adriamycin analog containing fluorine. Int. J. Pharm., 103, 147-154 (1994).
3. E.J. Yoon, E.D. Lee, W.H. Yoon, H.J. Shim, S.D. Lee, W.B. Kim, J. Yang and M.G. Lee, Pharmacokinetics, tissue distribution and biliary excretion of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM to dogs. A new adriamycin analog containing fluorine. Int. J. Pharm., 109, 181-187 (1994).
4. Y.G. Kim, E.J. Yoon, W.H. Yoon, H.J. Shim, S.D. Lee, W.B. Kim, J. Yang and M.G. Lee, Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or proteincalorie malnutrition rats. Biopharm. Drug Dispos., 17, 183-195 (1996).
5. S.D. Lee, J.B. Park, W.I. Lee, H.J. Shim, E.D. Lee, J.J. Lee, W.B. Kim, J. Yang, C.-K. Kim and M.G. Lee, Pharmacokinetics and antitumor activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice. Biopharm. Drug Dispos., 16, 489-505 (1995).
6. E.J. Yoon, W.I. Lee, H.J. Shim, S.D. Lee, W.B. Kim, J. Yang and M.G. Lee, Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Biopharm. Drug Dispos., 17, 373-420 (1996).
7. S.D. Lee, W.I. Lee, H.J. Shim, E.D. Lee, W.B. Kim, J. Yang, C.-K. Kim and M.G. Lee, Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. J. Clin. Pharm. Ther., 21, 201-213 (1996).
8. E.J. Yoon, H.J. Shim, J.J. Lee, S.D. Lee, W.B. Kim, J. Yang and M.G. Lee, Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. Drug Metab. Dispos., 25, 66-74 (1997).
9. Y.M. Choi, S.H. Lee and M.G. Lee, Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. J. Pharm. Sci., 80, 638-642 (1991).
10. Y.M. Choi, S.H. Lee, S.H. Jang and M.G. Lee, Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of bumetanide in rats. Biopharm. Drug Dispos., 12, 311-324 (1991).
11. S.H. Lee and M.G. Lee, Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemidu in rats. Biopharm. Drug Disposit., 18, 371-386 (1997).
12. J.F. Williams, S. Lowitt and A. Szentivanyi, Effect of phenobarbital and 3-methylcholanthrene pretreatment on the plasma half-life and urinary excretion profile of theophylline and its metabolites in rats. Biochem. Pharmacol., 28, 2935-2940 (1979).
13. C. Lambert, G. Caille and P. du Souich, Nonrenal clearance of furosemide as a course of diuretic response variability in rat. J. Pharmacol. Exp. Ther., 222, 232-236 (1982).
14. B.N. La Du, H.G. Mandel and E.L. Way, Fundamentals of Drug Metabolism and Drug Disposition, Williams and Wilkins, Baltimore, MD, 1971, p. 269.
15. S.H. Kim, Y.M. Choi and M.G. Lee, Pharmacokinetics and pharmacodynamics of furosemide in protein-caloric malnutrition. J. Pharmacokinet. Biopharm., 21, 1-17 (1993).
16. W.L. Chiou, Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharm. Sci., 67, 539-546 (1978).
17. W.L. Chiou, New calculation method for mean total body clearance of drugs and its application to dosage regimens. J. Pharm. Sci., 69, 90-91 (1980).